NASDAQ:RGNX REGENXBIO (RGNX) Stock Price, News & Analysis $6.76 -0.39 (-5.45%) Closing price 04:00 PM EasternExtended Trading$7.08 +0.33 (+4.81%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About REGENXBIO Stock (NASDAQ:RGNX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get REGENXBIO alerts:Sign Up Key Stats Today's Range$6.61▼$7.1850-Day Range$5.92▼$8.7052-Week Range$5.62▼$21.57Volume943,653 shsAverage Volume767,780 shsMarket Capitalization$338.58 millionP/E RatioN/ADividend YieldN/APrice Target$32.78Consensus RatingModerate Buy Company OverviewREGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.Read More… Remove Ads REGENXBIO Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreRGNX MarketRank™: REGENXBIO scored higher than 92% of companies evaluated by MarketBeat, and ranked 98th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingREGENXBIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageREGENXBIO has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about REGENXBIO's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for REGENXBIO are expected to grow in the coming year, from ($4.84) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of REGENXBIO is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of REGENXBIO is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioREGENXBIO has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about REGENXBIO's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.06% of the float of REGENXBIO has been sold short.Short Interest Ratio / Days to CoverREGENXBIO has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in REGENXBIO has recently decreased by 3.66%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldREGENXBIO does not currently pay a dividend.Dividend GrowthREGENXBIO does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.82 Percentage of Shares Shorted14.06% of the float of REGENXBIO has been sold short.Short Interest Ratio / Days to CoverREGENXBIO has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in REGENXBIO has recently decreased by 3.66%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News Sentiment0.38 News SentimentREGENXBIO has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for REGENXBIO this week, compared to 4 articles on an average week.Search InterestOnly 10 people have searched for RGNX on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added REGENXBIO to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, REGENXBIO insiders have not sold or bought any company stock.Percentage Held by Insiders13.13% of the stock of REGENXBIO is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.08% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about REGENXBIO's insider trading history. Receive RGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address RGNX Stock News HeadlinesChardan Capital Decreases Earnings Estimates for REGENXBIOMarch 29 at 2:09 AM | americanbankingnews.com5 Reasons To Buy Regenxbio Right NowMarch 26, 2025 | seekingalpha.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 1, 2025 | Porter & Company (Ad)REGENXBIO's (RGNX) Buy Rating Reiterated at Chardan CapitalMarch 23, 2025 | americanbankingnews.comREGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from AnalystsMarch 22, 2025 | americanbankingnews.comREGENXBIO: New Interim Data Reinforces Potential Of RGX-202 - Quick FactsMarch 21, 2025 | nasdaq.comRegenxbio reports data from Phase I/II portion of the Affinity Duchenne trialMarch 19, 2025 | msn.comREGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPYMarch 19, 2025 | prnewswire.comSee More Headlines RGNX Stock Analysis - Frequently Asked Questions How have RGNX shares performed this year? REGENXBIO's stock was trading at $7.73 at the beginning of 2025. Since then, RGNX stock has decreased by 12.7% and is now trading at $6.7470. View the best growth stocks for 2025 here. How were REGENXBIO's earnings last quarter? REGENXBIO Inc. (NASDAQ:RGNX) released its quarterly earnings results on Thursday, March, 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.26. The biotechnology company had revenue of $21.21 million for the quarter, compared to analysts' expectations of $23.70 million. REGENXBIO had a negative trailing twelve-month return on equity of 70.65% and a negative net margin of 283.19%. How do I buy shares of REGENXBIO? Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of REGENXBIO own? Based on aggregate information from My MarketBeat watchlists, some other companies that REGENXBIO investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY) and Humana (HUM). Company Calendar Last Earnings3/13/2025Today4/01/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RGNX CIK1590877 Webwww.regenxbio.com Phone(240) 552-8181FaxN/AEmployees370Year FoundedN/APrice Target and Rating Average Stock Price Target$32.78 High Stock Price Target$52.00 Low Stock Price Target$14.00 Potential Upside/Downside+358.4%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-263,490,000.00 Net Margins-283.19% Pretax Margin-283.37% Return on Equity-70.65% Return on Assets-41.68% Debt Debt-to-Equity RatioN/A Current Ratio3.05 Quick Ratio3.05 Sales & Book Value Annual Sales$83.33 million Price / Sales4.30 Cash FlowN/A Price / Cash FlowN/A Book Value$7.09 per share Price / Book1.01Miscellaneous Outstanding Shares50,086,000Free Float43,040,000Market Cap$358.11 million OptionableOptionable Beta1.35 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:RGNX) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share REGENXBIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.